News stories about TESARO (NASDAQ:TSRO) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. TESARO earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.7376809030724 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

A number of research firms have recently weighed in on TSRO. Gabelli began coverage on TESARO in a research note on Friday, July 7th. They issued a “buy” rating and a $175.00 target price for the company. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Wedbush upgraded TESARO to an “outperform” rating and set a $168.00 price target on the stock in a research report on Monday, June 5th. Credit Suisse Group set a $198.00 price target on TESARO and gave the stock a “buy” rating in a research note on Wednesday, July 19th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $199.00 price target on shares of TESARO in a research note on Sunday, September 10th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $171.42.

TESARO (NASDAQ:TSRO) opened at 129.10 on Monday. The company’s market cap is $6.99 billion. TESARO has a 12 month low of $96.52 and a 12 month high of $192.94. The stock has a 50 day moving average price of $121.03 and a 200 day moving average price of $138.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.28) EPS. Analysts anticipate that TESARO will post ($8.60) earnings per share for the current fiscal year.

In other TESARO news, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of TESARO stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total value of $70,211.20. Following the sale, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders have sold 35,692 shares of company stock valued at $4,628,976 in the last ninety days. Insiders own 40.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at


TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.